The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 26, 2025

Filed:

Jan. 07, 2020
Applicant:

Exocure Sweden Ab, Gothenburg, SE;

Inventors:

Kyong-Su Park, Gothenburg, SE;

Rossella Crescitelli, Gothenburg, SE;

Jan Lötvall, San Diego, CA (US);

Assignee:

Exocure Sweden AB, Goeteborg, SE;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/108 (2006.01); A61K 39/00 (2006.01); A61K 39/104 (2006.01); A61K 39/39 (2006.01); A61P 11/00 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); C12N 1/20 (2006.01); C12N 5/0784 (2010.01); C12R 1/19 (2006.01); C12R 1/385 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0258 (2013.01); A61K 39/0011 (2013.01); A61K 39/104 (2013.01); A61P 11/00 (2018.01); A61P 31/04 (2018.01); A61P 35/00 (2018.01); C12N 1/20 (2013.01); C12N 5/0639 (2013.01); A61K 39/39 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/57 (2013.01); C12N 2501/22 (2013.01); C12N 2506/1353 (2013.01); C12R 2001/19 (2021.05); C12R 2001/385 (2021.05);
Abstract

Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and/or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.


Find Patent Forward Citations

Loading…